PT  - JOURNAL ARTICLE
AU  - KAZUHIRO SHIMADA
AU  - TAKASHI ISHIKAWA
AU  - AKIMITSU YAMADA
AU  - SADATOSHI SUGAE
AU  - KAZUTAKA NARUI
AU  - DAISUKE SHIMIZU
AU  - TAKASHI CHISHIMA
AU  - ITARU ENDO
TI  - Matrix-producing Carcinoma as an Aggressive Triple-negative Breast Cancer: Clinicopathological Features and Response to Neoadjuvant Chemotherapy
AID  - 10.21873/anticanres.13536
DP  - 2019 Jul 01
TA  - Anticancer Research
PG  - 3863--3869
VI  - 39
IP  - 7
4099  - http://ar.iiarjournals.org/content/39/7/3863.short
4100  - http://ar.iiarjournals.org/content/39/7/3863.full
SO  - Anticancer Res2019 Jul 01; 39
AB  - Background: Breast matrix-producing carcinomas (MPCs) are rare, and usually triple-negative (TNBC; i.e. oestrogen receptor-, progesterone receptor-, and human epidermal growth factor receptor 2-negative). This study evaluated the clinical features, immunohistochemical profiles, and pathological response to neoadjuvant chemotherapy (NAC) of patients with MPCs. Patients and Methods: Five MPCs were identified among 247 patients with TNBC receiving anthracycline- and taxane-based NAC. Pathological response was assessed using surgical specimens. Results: All tumours were histological grade 3 according to pre-treatment core biopsies. Mean Ki-67 and p53 positivity were 65% and 90%, respectively. All tumours were TNBC, and epidermal growth factor receptor-, cytokeratin 5/6-, and vimentin-positive. Grade 3 (pathological complete response) was achieved in 0% (0/5) and 32% (77/242) of those with MPCs and with TNBCs of no specific histological type, respectively, and grade 1a (poor response) in 80% (4/5) and 13% (31/242), respectively. Conclusion: MPCs are basal-type TNBCs expressing epithelial–mesenchymal transition markers, with a poor response to standard NAC. Further studies are needed to improve the treatment of this rare but aggressive tumour.